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Intradermal Delivery of Plasmid VEGF165
by Electroporation Promotes Wound Healing
Bernadette Ferraro1, Yolmari L Cruz1, Domenico Coppola2 and Richard Heller1,3
Department of Molecular Medicine, University of South Florida, Tampa, Florida, USA; 2Department of Anatomic Pathology, H. Lee Moffitt
Cancer Center, Tampa, Florida, USA; 3Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, Virginia, USA
1

Skin flaps are extensively used in reconstructive surgeries to repair large defects and deep wounds, but severe
ischemia and necrosis often results in loss of the transplanted tissue. Thus, skin flap models are often used to
study the biology of healing and necrosis of acute ischemic wounds. Delivery of exogenous vascular endothelial growth factor (VEGF) to areas of ischemia has shown
promise for promoting therapeutic angiogenesis, but its
expression must be tightly regulated to avoid adverse
effects. In this study, plasmid DNA encoding VEGF165
(pVEGF) was delivered to the ischemic skin of a rat skin
flap model by intradermal injection followed by electroporation (EP) (pVEGFE+). Treatment with pVEGFE+
significantly increased VEGF expression for 5 days after
delivery compared to injection of pVEGF without EP
(pVEGFE−). The short-term increase in VEGF was sufficient to mediate an upregulation of endothelial nitric
oxide synthase, an angiogenic factor that increases vascular permeability. pVEGFE+ significantly increased skin
flap perfusion at both days 10 and 14 postoperatively.
The observed increase in perfusion with pVEGFE+ correlated with an increase in skin flap healing and survival.
Our results demonstrate that pVEGFE+ is a potential
nonviral noninvasive therapy to increase perfusion and
healing of skin flaps and ischemic wounds.
Received 22 December 2008; accepted 12 January 2009;
published online 24 February 2009. doi:10.1038/mt.2009.12

Introduction
Skin flaps are frequently used in plastic and reconstructive surgeries to repair large skin defects and deep wounds formed from
injuries, surgeries, ulcerations, or congenital defects. In skin flap
surgery, a piece of full thickness skin is transferred to the affected
area while remaining attached to the donor site by a vascular
pedicle. Skin flaps are grouped into two general categories, axial
and random. Axial skin flaps are perfused by a single direct subcutaneous artery through the vascular pedicle while random skin
flaps (RSFs) are perfused by small musculocutaneous or septocutaneous perforators.1 In both axial and RSFs, insufficient arterial supply and inadequate venous drainage can lead to distal skin
flap ischemia and necrosis.2 Despite the intense use of skin flaps

as a model to study the healing and necrosis of ischemic wounds,
a viable clinical solution to prevent distal necrosis and enhance
healing remains elusive. Gene therapy techniques delivering exogenous angiogenic growth factors and cytokines, such as vascular
endothelial growth factor (VEGF), to skin flaps are currently being
investigated to increase skin flap perfusion and healing.3
In vascular endothelial cells, VEGF induces cell proliferation,
promotes cell migration, differentiation, and inhibits apoptosis.
VEGF expression is potentiated in response to hypoxia, by activated oncogenes, and by a variety of cytokines. The angiogenic and
blood vessel permeability effects of VEGF are mediated by binding to the tyrosine kinase receptors VEGF Receptor 1 and VEGF
Receptor 2. Signaling through VEGF Receptor 1 mediates VEGFinduced migration of monocytes while signaling through VEGF
Receptor 2 mediates the mitogenic and vessel permeability effects
of VEGF.4 VEGF-mediated increases in vascular permeability are
largely due to an increase in the downstream angiogenic growth
factor endothelial nitric oxide synthase (eNOS) that mediates an
increase in the release of the vasodilator nitric oxide.5,6 In vivo
and in vitro studies demonstrated that the level of VEGF expression must be finely regulated to induce successful angiogenesis7–10
and, more recently, that high levels of VEGF may inhibit new vessel stabilization.11 High levels of constitutive VEGF expression
can result in edema,12 formation of hemangiomas, and unstable
immature vessels.7–11 In contrast, low levels or premature cessation of VEGF expression results in regression of the newly formed
vessels.13 Thus, the development of a gene therapy approach that
allows for tight control over expression level and duration would
be advantageous for VEGF-mediated therapeutic angiogenesis.
Direct injection of naked plasmid DNA has been intensively
investigated as a gene delivery approach for the treatment of a
variety of diseases. One drawback to this approach is that inefficient uptake of the plasmid by the cells results in low levels of gene
expression.14 In vivo electroporation (EP) has been successfully
used to increase the uptake and expression of naked plasmid DNA
in the skin and other target tissues. Electrically mediated delivery
of plasmid DNA to the skin could potentially be used to deliver
plasmids with therapeutic potential to treat a variety of diseases
and has recently shown promise in a clinical trial.15 In previous
work, we developed a novel electrode, the four-plate electrode,
and optimized conditions using this electrode for cutaneous gene
delivery with minimal tissue damage.16 Here, we show that using
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the four-plate electrode to deliver pVEGFE+ to the ischemic skin
of a modified McFarlane17,18 8 cm × 3 cm RSF increases VEGF
expression more than pVEGFE−. Although the increase in VEGF
expression was short-term, it was sufficient to induce an endogenous angiogenic response and increase perfusion and survival of
the distal area of the RSF. These results suggest that pVEGFE+
is a potential novel therapeutic approach to increase healing and
decrease necrosis of ischemic wounds and RSFs.
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Plasmids encoding a wide variety of genes with therapeutic potential, including VEGF,19 have been successfully delivered to skeletal
muscle by intramuscular injection with EP.20 Delivery of plasmids
with EP significantly increased transgene expression compared
to injection of the plasmid alone. Before delivering plasmid DNA
encoding VEGF165 (pVEGF) to the RSF model, we first evaluated
whether it could increase VEGF levels in vitro (data not shown)
and in vivo by delivering pVEGFE+ and pVEGFE− to the rat gastrocnemius muscle. On days 2, 5, 7, and 10 after pVEGF delivery,
muscle was excised from the delivery site and assayed for VEGF
expression by enzyme-linked immunosorbent assay. Compared
to pVEGFE−, pVEGFE+ significantly increased VEGF expression
at both days 2 and 5 after delivery (Figure 1a) but VEGF levels
returned to background levels by day 7 after delivery (data not
shown). Because pVEGFE+ successfully increased VEGF expression in gastrocnemius muscle we then investigated whether the
same increase could be achieved with pVEGFE+ in the skin of the
RSF model.
Skin flaps were treated on day 2 postoperatively. On days 2, 5,
8, and 12 after treatment, skin samples from the delivery sites were
harvested and assayed for VEGF expression using an enzymelinked immunosorbent assay that specifically detects human
VEGF165. Necrosis prevented all sites from being harvested, especially in the pVEGFE− group at later time points. At both 2 and
5 days after delivery, VEGF expression was significantly higher in
the pVEGFE+ treatment group compared to the pVEGFE− treatment group (P < 0.05, both time points). VEGF expression was
determined for each treatment group for delivery to the proximal
area, closest to the RSF pedicle, and distal area, farthest from the
RSF pedicle. Interestingly, 2 days after pVEGF delivery, VEGF
expression was significantly higher in the distal area of the RSF,
compared to the proximal area, for the pVEGFE+ treatment
group (P < 0.05). In the pVEGFE− treatment group, there was a
twofold increase in VEGF expression in the distal area, but this
increase was not statistically significant (P = 0.157). The level of
VEGF expression achieved with pVEGFE+ in the distal area of
the RSF was similar to the level and duration observed in the
gastrocnemius (Figure 1a,b). Compared to day 2 after delivery
there was an overall significant decrease in VEGF expression at
day 5 after delivery (P < 0.05, both treatment groups in both the
proximal and distal areas) but levels were still significantly higher
with pVEGFE+ (P < 0.05) (Figure 1b). At day 8 after delivery
there was not a significant increase in VEGF expression with
pVEGFE+ in either the proximal or distal area of the RSF, and by
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Results
Electrically mediated intradermal delivery of
pVEGF increases VEGF expression and promotes
a VEGF-mediated increase in eNOS expression
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Figure 1 VEGF expression kinetics. pVEGFE+ significantly increased
VEGF compared to pVEGFE−. (a) pVEGFE+ increased VEGF expression
in gastrocnemius muscle. Day 2: n = 6 per group. Day 5: pVEGFE−
n = 5; pVEGFE+ n = 4. (b) Two and 5 days after delivery VEGF expression was significantly greater with pVEGFE+ than pVEGFE− in the RSF.
VEGF expression was further increased in the distal region of the RSF.
pVEGFE−: day 2 proximal n = 8, distal n = 6; day 5 proximal n = 3, distal
n = 4; day 8 proximal n = 3, distal n = 2; and day 12 proximal and distal
n = 2. pVEGFE+: day 2 proximal n = 4, distal n = 7; day 5 proximal n = 7,
distal n = 6; day 8 proximal n = 3, distal n = 4; and day 12 both proximal and distal n = 3. (c) pVEGFE+ significantly increased eNOS expression in the distal area of the RSF 2 days after delivery; n = 7 per group
per time point. For groups with n ≤ 3 the mean ± SD is reported. For
groups with n > 3 the mean ± SEM is reported. *P < 0.05 compared to
pVEGFE−. ‡P < 0.01 compared to pVAXE+. eNOS, endothelial nitric oxide
synthase; pVEGFE+, mice injected with pVEGF followed by electroporation; pVEGFE−, rats injected with pVEGF without electroporation; VEGF,
vascular endothelial growth factor; pVAXE+, empty vector control.

day 12 only background levels of VEGF were detected for both
pVEGFE+ and pVEGFE−. VEGF expression was not detected
when the vector backbone lacking the VEGF cDNA insert was
delivered to the RSF with EP (pVAXE+), in the skin of untreated
www.moleculartherapy.org vol. 17 no. 4 apr. 2009
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controls (P-E−), or in serum samples at any time point during the
study (data not shown).
Both in vitro and in vivo studies6,21 have shown that increases
in VEGF can increase levels of eNOS. To determine whether
pVEGFE+ and pVEGFE− increased eNOS in the RSF, skin samples
from the distal area of the RSF were assayed for eNOS by enzymelinked immunosorbent assay at days 2 and 5 after delivery. Two
days after delivery eNOS was significantly higher with pVEGFE+
treatment compared to pVEGFE− treatment (P < 0.05), but by
day 5 after delivery eNOS levels were similar in the pVEGFE+
and pVEGFE− treatment groups (Figure 1c). The application of
an electric field to tissues alone can transiently induce expression
of some genes22 but pVAXE+ did not increase eNOS in the RSF
model (P < 0.01).
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Electrically mediated delivery of pVEGF promotes
healing and decreases necrosis
Visual assessment of skin flap viability over the time course of the
study showed a clear decrease in distal necrosis in the pVEGFE+
treatment group compared to control groups (Figure 3a). The
surviving region of the distal area of the RSFs, corresponding to
~25% of the total skin flap area, was quantitated on days 7 and
14 postoperatively (Figure 3b). To quantitate the percent survival
of the distal area, the area of skin with normal texture and color
was expressed as a percent of the total distal area. Nonsurviving
areas were defined as dark, rigid necrotic skin or scabbed necrotic
lesions and surviving areas were defined as normal in texture and
color. The pVEGFE+ treatment increased distal RSF survival at
day 7 postoperatively (89.4 ± 4.3, P < 0.05) compared to pVEGFE−
(56.6 ± 10.6), pVAXE+ (59.3 ± 9.8) and P-E− (60.2 ± 9.6). The surviving area in all treatment groups increased ~5–10% at day 14
Molecular Therapy vol. 17 no. 4 apr. 2009
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Electrically mediated delivery of pVEGF increases
perfusion to the distal area of the RSF
Therapeutic angiogenesis aims to increase perfusion to the affected
area thereby decreasing the effects of ischemia and preventing
necrosis. Because RSF survival shows little change after day 15
postoperatively18 we monitored skin flap perfusion and healing
for 14 days postoperatively. pVEGFE+ resulted in the highest level
of VEGF expression in the distal area of RSFs which is more at
risk for ischemia and necrosis because it is farthest from the vascular pedicle. We next evaluated whether pVEGFE+ treatment
increased perfusion more than control treatments in the distal
area of the RSF, corresponding to ~25% of the total skin flap area.
A Laser Doppler Imager was used to measure perfusion preoperatively (baseline), immediately postoperatively (day 0) and on
days 2, 4, 7, 10, and 14 postoperatively. A sharp decrease in distal
perfusion was observed immediately postoperatively through day
4 postoperatively indicating that the RSF was effectively rendered
ischemic. Perfusion for each treatment group is reported as the
percent recovery of baseline (Figure 2a) and postoperative perfusion (Figure 2b). At days 10 and 14 postoperatively, perfusion was
significantly different between all treatment groups for both recovery of baseline and postoperative perfusion (P < 0.01). Perfusion
in the pVEGFE+ treatment group was significantly greater than
all controls on both days 10 and 14 postoperatively for both recovery of baseline (P < 0.01) and postoperative (P < 0.05) perfusion.
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Figure 2 pVEGFE+ increases perfusion. Perfusion was measured in the
distal region of the RSF by Laser Doppler Imaging at the indicated time
points. pVEGFE+ significantly increased recovery of (a) baseline and (b)
postoperative perfusion on days 10 and 14 postoperatively compared
to all controls; n = 7 per group, per time point. *P < 0.05, **P < 0.01
compared to all controls. pVEGFE+, rats injected with pVEGF followed by
electroporation; RSF, random skin flaps.

postoperatively, but healing was still greater and more consistent in
the pVEGFE+ group (95.2 ± 2.2) (P < 0.01) compared to pVEGFE−
(65.6 ± 9.3), pVAXE+ (70.6 ± 7.4) and P-E− (73.5 ± 4.1). Adverse
side effects associated with increased VEGF expression levels,
such as edema,7–10 were not observed by gross visual assessment
in any of the treatment groups. The mean percent survival of the
pVEGFE− group at day 7 postoperatively in our study is similar to
previously reported values delivering a plasmid encoding VEGF
to a similar RSF model.23 On day 14 postoperatively, skin samples
were excised 2-cm from the distal end of the RSFs for histological
analysis by hematoxylin–eosin staining (Figure 3c). If the skin was
necrotic at 2-cm from the distal end samples were excised near
the edge of the surviving border. Skin from the pVEGFE+ treatment group appeared healthy (Figure 3c, A,B) while skin from the
pVEGFE− treatment group showed evidence of acute inflammation, necrosis, and myonecrosis (Figure 3c, C–F).

Discussion
In addition to direct injection of plasmid DNA, the most prevalent methods of therapeutic delivery of VEGF to skin flaps documented in the literature are adenoviral-mediated gene transfer
and recombinant protein injection. These methods are also promising for increasing skin flap healing3,24,25 but have draw backs.
In human clinical trials, adenoviral vectors have caused inflammatory responses, formation of antibodies to the adenoviruses,
653
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transient fever,26 and hepatotoxicity.27 Also, adenoviral delivery
results in long-term and high levels of gene expression increasing the potential for the occurrence of the adverse side effects
associated with continuous unregulated VEGF expression.7–10
Recombinant VEGF protein injection has also shown beneficial
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effects on skin flap viability, but its use in a clinical setting is not
practical due to its short half-life, poor bioavailability, and consequently the need for frequent administration to sustain lasting
effects.28,29 Moreover, intravenous injection of recombinant VEGF
was more effective than local administration25 for decreasing
skin flap necrosis, which again raises the concern of pathological
angiogenesis that may result from systemic VEGF expression.7–10
Here, we have presented a novel therapeutic approach to
increase VEGF expression, induce an endogenous angiogenic
response, increase perfusion, and decrease necrosis of the distal
area of RSFs. The skin is an attractive target for delivery of plasmid DNA because it allows for enhanced control over expression
levels and aids in targeting expression to specific tissue areas.
Further, if higher expression levels are needed, the area treated
or number of treatments can be increased. Previous gene therapy studies delivered VEGF to skin flaps either preoperatively or
intraoperatively.3,24,25 Our study was the first to deliver pVEGF 2
days postoperatively. VEGF modulates the proliferative phase of
wound healing that begins 2–4 days after the wound is created, and
is characterized by angiogenesis, collagen deposition, granulation
tissue formation, epithelialization, and wound contraction.30 By
administering pVEGFE+ 2 days postoperatively, we timed VEGF
expression to peak during the beginning of the proliferative phase
of wound healing. Also, by administering treatment 2 days postoperatively, when the distal area of the skin flap is most hypoxic,31
we also determined that electrically mediated plasmid delivery to
a large area of ischemic skin is in fact possible. Our results demonstrate that pVEGFE+ significantly increased VEGF expression, compared to pVEGFE−, and that VEGF expression further
increased with distance from the vascular pedicle. Further, in the
distal area of the RSF pVEGFE+ resulted in similar levels of VEGF
expression as delivery to the gastrocnemius muscle (Figure 1a, b).
Higher VEGF expression in the distal area of the RSF, compared
to proximal region, could be due to hypoxia-induced stabilization of the VEGF mRNA or increased translation.32 The current
mechanisms described for increasing VEGF mRNA stability and
translation involve genetic regions not contained within the plasmid used in this study. It is possible that other currently unknown
mechanisms could enhance VEGF levels and may be responsible
for the increase in VEGF expression in the distal area, compared
to the less hypoxic proximal region. Importantly, VEGF expression was transient and not detected systemically, indicating that
the increase was localized to the delivery area, which decreases
the possibility of the adverse side effects that can result from high
levels and/or systemic VEGF.
Increases in eNOS resulting from pVEGFE+ and pVEGFE−
indicate the increase in VEGF expression resulting from these
treatments successfully stimulated an endogenous angiogenic
Figure 3 pVEGFE+ increases healing. (a) Representative images of
RSFs from each treatment group over the time course of the study.
(b) pVEGFE+ accelerated skin flap healing and decreased necrosis compared to all controls. Quantification of distal survival on days 7 and 14
postoperatively; n = 7 per group, per time point. *P < 0.05, **P < 0.01
compared to all controls. (c) Representative sections of skin excised
2-cm from the distal end of RSF stained with hematoxylin–eosin from the
pVEGFE+ (A,B) and pVEGFE− (C–F) treatment groups. pVEGFE+, mice
injected with pVEGF followed by electroporation; pVEGFE−, rats injected
with pVEGF without electroporation; RSF, random skin flaps.
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response. pVEGFE+ induces an earlier and more robust increase in
eNOS expression compared to pVEGFE− (Figure 1c). Our results
are consistent with reports that in vitro VEGF-induced upregulation of eNOS is time and dose dependent33 and with a study by
Huang et al.34 that demonstrated adenoviral delivery of VEGF165 to
RSFs increased eNOS. Relative to pVEGFE−, there was a 2.2-fold
increase in eNOS protein with pVEGFE+ in the distal area of the
RSF at day 2 after treatment that was mediated by a 6.6-fold increase
in VEGF protein (Figure 1b, c). Significant progress has been
made elucidating the mechanisms underlying VEGF-mediated
increases in eNOS, but many aspects of the complete mechanism
remain unclear despite the well-established role of this pathway in
wound healing and angiogenesis.34–36 In vivo34 and in vitro6,33 studies have shown that VEGF-mediated increases in eNOS protein
levels are typically two- to fivefold over background levels at an
optimal in vitro dosage. In the work presented here eNOS levels
with pVEGFE+ remain similar from day 2 to day 5 after treatment,
but increase with pVEGFE− over this time period, suggesting that
maximal levels of eNOS has been reached in the pVEGFE+ group
2 days after treatment. The small increase in eNOS levels, relative
to VEGF levels, may be due to inhibition of eNOS production by
high levels of nitric oxide.37 Also, the persistence of eNOS expression in the pVEGFE+ and pVEGFE− treatment groups at day 5
after treatment, despite a decrease in VEGF expression, may be
due to a VEGF-mediated increase in eNOS mRNA stability.6 eNOS
mRNA has an normal half-life of 48 hours38 and further extending
the half-life would allow for increases in eNOS protein to persist
despite a decrease in VEGF levels.
The early increase in eNOS observed with pVEGFE+ could
contribute to the increased perfusion and healing observed at
the later time points. eNOS production of nitric oxide is important in the early stages of skin flap healing39 and contributes to
maintaining peripheral skin flap circulation.40 Another possible
mechanism for the increased perfusion and healing of the RSF
after treatment with pVEGFE+ is increased neovascularization.
We did not observe a significant increase in vessel density (data
not shown) on day 14 of the study in skin samples harvested 2-cm
from the RSFs distal end. Other groups delivering exogenous
VEGF to wound healing models have reported the same phenomenon of increased healing without an associated increase in vessel
density24,41 although other studies do not discuss changes in capillary density. To prevent ischemic necrosis there must be adequate
perfusion pressure to the distal region of the skin flap.42 In this
study, increased eNOS, and subsequently increased vasodilation,
could be the primary mechanism of the pVEGFE+ mediated
increase in perfusion and healing, but determination of the exact
mechanism will require further studies.
The end goal of exogenous VEGF delivery to ischemic tissue
is to increase the amount of nutrients supplied to the affected area
and the rate of waste product removal by increasing vasodilation,
vascular permeability, and angiogenesis. The strategy developed
here to deliver VEGF to ischemic skin offers an attractive alternative to viral and recombinant protein approaches because it allows
for control of localized expression level and duration. Further,
direct injection of pVEGF with EP significantly increased VEGF
expression levels, compared to direct injection of pVEGF without EP, and circumvents the adverse side effects and practicality
Molecular Therapy vol. 17 no. 4 apr. 2009
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issues associated with viral and recombinant protein delivery
approaches. In summary, the pVEGFE+ treatment significantly
increased VEGF expression for 5 days after delivery and this
short-term increase was sufficient to significantly increase eNOS,
compared to pVEGFE− treatment 2 days after delivery. Further,
pVEGFE+ significantly increased recovery of baseline and postoperative perfusion as well as healing compared to all control
treatment groups. In conclusion, electrically mediated intradermal delivery of pVEGF is a potential noninvasive therapeutic
approach to increase perfusion and healing of ischemic wounds.

Materials and Methods
Cloning of the VEGF165 plasmid. The human VEGF165 plasmid was
cloned by subcloning the hEF1–HTLV–hVEGF165 sequence from
pBLAST49–hVEGF (Invivogen, San Diego, CA) into the backbone of
pVAX1 (Invitrogen, Carlsbad, CA). The cytomegalovirus promoter was
previously removed from pVAX to create a promoterless pVAX1. The
empty vector control (pVAXE+) is the pVAX1 backbone containing the
hEF1–HTLV promoter.
Animal model. All procedures were approved by the Animal Use and Care

Committee of the University of South Florida College of Medicine. A total
of 51 male Sprague–Dawley rats (275–300 g) were used in this study. Eleven
rats were used to determine whether delivery of pVEGF to the gastrocnemius muscle resulted in increased VEGF expression. Twelve rats were used
to evaluate VEGF and eNOS expression kinetics in the RSF and 28 rats
were used for analysis of distal skin flap perfusion and survival. Prior to
surgery and all procedures, animals were anesthetized with 2.5–3.0% isoflurane in oxygen. Surgeries were performed using standard aseptic technique. To create the rostral-based single pedicle RSF the left lateral flank of
the rat was shaved and an 8 cm by 3 cm template was traced with a surgical
marker. Full thickness incisions were made along the traced template lines.
The flap was then elevated and sutured back to its bed using simple interrupted and running stitches with 4-0 nonabsorbable sutures.

Plasmid delivery. Delivery of pVEGF to the gastrocnemius muscle. The gastrocnemius muscle was exposed using a 1-cm incision. Animals received
one 50-μL injection of pVEGF (2 mg/ml) in sterile saline using a 25 gauge,
5/8-inch length needle. The injection site was marked with one stitch using
a 4-0 nonabsorbable suture to later identify the delivery site to be excised for
protein extraction and assaying VEGF expression. For pVEGFE+ a fourneedle electrode array with 6-mm gap width was then placed around the
delivery site and eight 20-ms pulses were delivered at 200 V/cm. Delivery of
pVEGF to the RSF. Two days after surgery animals were randomized into
one of four treatment groups (pVEGFE+, pVEGFE−, pVAXE+ or P-E−)
and received 4–50 μL intradermal injections of plasmid DNA (2 mg/ml)
in sterile saline (except for P-E− which did not receive any treatment).
All injections were performed using a 25 gauge, 5/8-inch length needle
and were centered along the midline of the skin flap at 1, 3, 5, and 7 cm
from the RSF pedicle. Injection sites were marked with a surgical marker if
they were to be excised later for protein extraction. Where noted proximal
delivery sites are those at 1 and 3 cm from the pedicle and distal delivery
sites are those at 5 and 7 cm from the pedicle. After injection of plasmid
DNA, the four-plate electrode16 was used to deliver 8–20 ms electric pulses
at 200 V/cm to pVAXE+ and pVEGFE+ treatment groups.
VEGF and eNOS protein expression. At the indicated time points the

delivery sites were excised and snap frozen on dry ice. Tissue samples were
homogenized in 1–2 ml of lysis buffer (150 mmol/l NaCl, 20 mmol/l sodium
phosphate pH 7.4, 10% glycerol, 1% NP-40 and protease inhibitors (Roche,
Indianapolis, IN)). Homogenates were then centrifuged at 4 °C for 10 minutes
at 10,000 rpm. The supernatants were removed and assayed for protein expression using commercially available enzyme-linked immunosorbent assays for
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human VEGF165 (DY293B, R&D Systems, Minneapolis, MN) and eNOS
(DEN00, R&D Systems) according to the manufacturer’s instructions.

4.

Skin flap perfusion. A Laser Doppler Perfusion Imager (Moor Instruments,

5.

Devon, UK) was used to record perfusion at indicated time points. A low
intensity (2 mW) laser light beam (λ = 632.8 nm) scanned the surface of
the skin without contact at a standardized working distance of 28 cm. Scan
modus was set at 10 ms/pixel and resolution at 256 × 256 pixels. Three
scans were completed per time point for each animal and average perfusion in arbitrary units (flux) for the distal region of the skin flap (5-cm2
area) was determined for each time point. Baseline perfusion was assessed
immediately before surgery. Perfusion results are reported as the percentage of perfusion units relative to baseline or postoperative perfusion (normalized to 100%).

Skin flap survival. The percent survival of the distal 5-cm2 area of the skin

flaps was quantitated on days 7 and 14 after surgery. Areas dark in color
and/or covered in scabs were defined as necrotic/nonsurviving areas. Areas
with normal skin texture and color were defined as surviving areas. The
surviving areas were calculated using the Moor imaging software (Moor
Instruments) and pictures were recorded using a digital camera (Nikon,
Melville, NY).
Histology. Two weeks postoperatively animals were humanely euthanized.

Tissue samples were excised from the center of the skin flap, 2 cm from the
distal end, fixed in 10% neutral buffered formalin for at least 12 hours at
room temperature, embedded in paraffin and sectioned (4 μm). If the tissue was necrotic at 2 cm from the distal end, samples were excised at the
border of the necrotic and surviving tissue. Sections were then stained with
hematoxylin and eosin using standard protocols. Stained sections were
analyzed using a standard light microscope (Olympus BX51; Olympus,
Center Valley, PA) and representative fields photographed with a Spot
Insight 2 digital camera (Diagnostic Instruments, Sterling Heights, MI).
Statistical analyses. All values are reported as the mean ± SEM unless
otherwise noted. Analysis of VEGF expression was completed using a
two-tailed Student’s t-test. Analysis of eNOS expression and distal perfusion was completed by ANOVA with a post hoc Dunnett’s test to adjust
for multiple comparisons to one control group (pVEGFE+). Statistical
significance was assumed at P < 0.05. Analysis of distal RSF survival was
completed using the Mann–Whitney–Wilcoxon test. For distal survival,
a post hoc Bonferroni–Dunn correction was used to correct for multiple
comparisons. All statistical analysis was completed using the Statistical
Package for the Social Sciences (SPSS, Chicago, IL).
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